The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Research of the clinical effect of trimebutine and oryzanol as a treatment on patients with irritable bowel syndrome
Author(s): 
Pages: 6699-6700
Year: Issue:  32
Journal: Jilin Medical Journal

Keyword:  Trimebutine maleateOryzanolCompound Eosinophil-LactobacillusIrritable bowel syndrome;
Abstract: Objective To observe the clinical effect of trimebutine maleate capsules,oryzanol joint Compound Eosinophil-Lactobacillus tablets treating the patients with irritable bowel syndrome. Methods 120 cases of irritable bowel syndrome,60 cases in the treatment group,60 cases in the control group. The treatment group received trimebutine maleate,oryzanol and Compound Eosinophil-Lactobacillus,the control group only received trimebutine maleate and oryzanol. Results The total effective rate of the treatment group was 86.67% and control group was 71.67%,the total effective rate of the two groups were statistically significant differences in their efficacy(P<0.05).Conclusion Trimebutine maleate capsules,oryzanol joint compound Lactobacillus acidophilus tablets in the treatment of IBS have a significant effect,with better compliance and fewer side effects. It is significantly better than trimebutine maleate capsules single joint oryzanol treatment,and it is worth to promote and apply.
Related Articles
No related articles found